Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
Copyright © 2016 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Study | Stent type | No. of patients | PFC type | PFC size, mm | TSR, % | CSR, % | ADR, n (%) |
---|---|---|---|---|---|---|---|
Yamamoto et al. (2013) [24] | Nagi | 9 | Pseudocyst/WON | 146a) | 100 | 77 | Late 2 (22) |
Chandran et al. (2015) [20] | Nagi | 47 | Pseudocyst/WON | 100b) | 98.1 | 76.6 | 10 (21)/14 (29)c) |
Walter et al. (2015) [17] | Axios | 61 | Pseudocyst/WON | 90b) | 98 | 93/81d) | 5 (9) |
Siddiqui et al. (2015) [18] | Axios | 82 | Pseudocyst/WON | 118a) | 97.5 | 98.7 | 4 (28.5)/9 (13.2)d) |
Shah et al. (2015) [7] | Axios | 33 | Pseudocyst/WON | 90a) | 91 | 93 | 5 (15) |
Bapaye et al. (2015) [14] | Nagi | 19 | Pseudocyst/WON | 107a) | 100 | 100 | 2 (10.5) |
Itoi et al. (2012) [13] | Axios | 15 | Pseudocyst | 98a) | 100 | 100 | 1 (6.6) |
Study | Stent type | No. of patients | PFC type | PFC size, mm | TSR, % | CSR, % | ADR, n (%) |
---|---|---|---|---|---|---|---|
Yamamoto et al. (2013) [24] | Nagi | 9 | Pseudocyst/WON | 146 |
100 | 77 | Late 2 (22) |
Chandran et al. (2015) [20] | Nagi | 47 | Pseudocyst/WON | 100 |
98.1 | 76.6 | 10 (21)/14 (29) |
Walter et al. (2015) [17] | Axios | 61 | Pseudocyst/WON | 90 |
98 | 93/81 |
5 (9) |
Siddiqui et al. (2015) [18] | Axios | 82 | Pseudocyst/WON | 118 |
97.5 | 98.7 | 4 (28.5)/9 (13.2) |
Shah et al. (2015) [7] | Axios | 33 | Pseudocyst/WON | 90 |
91 | 93 | 5 (15) |
Bapaye et al. (2015) [14] | Nagi | 19 | Pseudocyst/WON | 107 |
100 | 100 | 2 (10.5) |
Itoi et al. (2012) [13] | Axios | 15 | Pseudocyst | 98 |
100 | 100 | 1 (6.6) |
PFC, pancreatic fluid collection; TSR, technical success rate; CSR, clinical success rate; ADR, adverse reaction rate; WON, walled-off necrosis. Mean; Median; Early (<24 hours)/delayed (>24 hours) adverse events; Pancreatic pseudocyst/wall-of necrosis.